WebS3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 –Dezember 2024 5 Quellen: Bruera, E., J. S. Willey, J. L. Palmer and M. … Web© AGO e. V. in der DGGG e.V. sowie in der DKG e.V. Guidelines Breast Version 2024.1D Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome
S3-Leitlinie: Endokrine Therapie des primären …
Webbreast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat. 2013;139(3):779 -87. doi: 10.1007/s10549-013-2589-8. 2. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first -line chemotherapy . Web he is on the roll
AGO - Die Arbeitsgemeinschaft Gynäkologische Onkologie
WebJul 5, 2024 · Die adjuvante endokrine Therapie mit Tamoxifen und AI reduziert die Rezidivwahrscheinlichkeit relativ um ca. 40 % und die Wahrscheinlichkeit des ... AGO Organkommission Mamma (2024) Therapieempfehlungen der AGO Organkommission Mamma. ... (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) S3-Leitlinie … WebCervical Cancer: ESMO Clinical Practice Guidelines. Published in 2024 – Ann Oncol (2024) 28 (suppl 4): iv72–iv83. Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries. These updated guidelines focus on the management of local/locoregional and ... WebSep 30, 2024 · The authors refer to the current recommendations of the Breast Cancer Working Group for Gynecological Oncology (AGO Mamma) published in March 2024. The AGO Breast Cancer Guidelines are updated annually. he is on trial